{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:31Z","timestamp":1790963611452,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1,11]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Ibrutinib has modest activity in FL with low response rates in rituximab-refractory patients. CARD11 mutations predict for lack of response to ibrutinib.<\/jats:p>","DOI":"10.1182\/blood-2017-09-804641","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T09:25:40Z","timestamp":1509009940000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":142,"title":["Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial"],"prefix":"10.1182","volume":"131","author":[{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Costello","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy R.","family":"LaPlant","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"University of Toronto, Princess Margaret Cancer Centre, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona, Phoenix, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lim S.","family":"Thye","sequence":"additional","affiliation":[{"name":"National Cancer Center Singapore, Singapore;"},{"name":"Office of Education, Duke-National University of Singapore Graduate Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6299-9230","authenticated-orcid":false,"given":"Kilannin","family":"Krysiak","sequence":"additional","affiliation":[{"name":"Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;"},{"name":"McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;"},{"name":"McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qi","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-446X","authenticated-orcid":false,"given":"Malachi","family":"Griffith","sequence":"additional","affiliation":[{"name":"Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;"},{"name":"McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0843-4271","authenticated-orcid":false,"given":"Obi L.","family":"Griffith","sequence":"additional","affiliation":[{"name":"Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;"},{"name":"McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-7510","authenticated-orcid":false,"given":"Felicia","family":"Gomez","sequence":"additional","affiliation":[{"name":"Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;"},{"name":"McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-2887","authenticated-orcid":false,"given":"Todd A.","family":"Fehniger","sequence":"additional","affiliation":[{"name":"Division of Oncology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111904184984900_B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2019111904184984900_B2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"K\u00fcppers","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"2-3","key":"2019111904184984900_B3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/IR:23:2-3:147","article-title":"Regulation of B lymphocyte development and activation by Bruton\u2019s tyrosine kinase","volume":"23","author":"Khan","year":"2001","journal-title":"Immunol Res"},{"issue":"4","key":"2019111904184984900_B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2019111904184984900_B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111904184984900_B6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111904184984900_B7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111904184984900_B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1213.1213","article-title":"Single-agent ibrutinib demonstrates efficacy and safety in patients with relapsed\/refractory marginal zone lymphoma: a multicenter, open-label, phase 2 study [abstract]","volume":"128","author":"Noy","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111904184984900_B9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"29","key":"2019111904184984900_B10","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111904184984900_B11","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","article-title":"Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma","volume":"99","author":"Zhu","year":"2002","journal-title":"Blood"},{"issue":"16","key":"2019111904184984900_B12","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood-2015-04-640805","article-title":"Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells","volume":"126","author":"Linley","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2019111904184984900_B13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2015-04-640912","article-title":"DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma","volume":"126","author":"Amin","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111904184984900_B14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111904184984900_B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.156.156","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma [abstract]","volume":"120","author":"Fowler","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111904184984900_B16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111904184984900_B17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2019111904184984900_B18","author":"Vogelstein","year":"2013"},{"issue":"7","key":"2019111904184984900_B19","doi-asserted-by":"crossref","first-page":"e1004274","DOI":"10.1371\/journal.pcbi.1004274","article-title":"Genome Modeling System: a knowledge management platform for genomics","volume":"11","author":"Griffith","year":"2015","journal-title":"PLOS Comput Biol"},{"issue":"4","key":"2019111904184984900_B20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2019111904184984900_B21","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","article-title":"GenVisR: genomic visualizations in R","volume":"32","author":"Skidmore","year":"2016","journal-title":"Bioinformatics"},{"issue":"1","key":"2019111904184984900_B22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ng.3466","article-title":"Exploring genomic alteration in pediatric cancer using ProteinPaint","volume":"48","author":"Zhou","year":"2016","journal-title":"Nat Genet"},{"issue":"15","key":"2019111904184984900_B23","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111904184984900_B24","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"29","key":"2019111904184984900_B25","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1073\/pnas.1002057107","article-title":"B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression","volume":"107","author":"Irish","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019111904184984900_B26","author":"Gopal","year":"2016"},{"issue":"23","key":"2019111904184984900_B27","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.V126.23.2706.2706","article-title":"Long-term follow-up and analysis of dose groups with ibrutinib in relapsed follicular lymphoma [abstract]","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111904184984900_B28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"2019111904184984900_B29","author":"Ujjani","year":"2016"},{"key":"2019111904184984900_B30","author":"Lenz","year":"2008"},{"key":"2019111904184984900_B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-12-546309","article-title":"Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients","author":"de Miranda","year":"2014"},{"key":"2019111904184984900_B32","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1038\/ncomms9866","article-title":"Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution","volume":"6","author":"Kasar","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"2019111904184984900_B33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"42","key":"2019111904184984900_B34","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"2019111904184984900_B35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111904184984900_B36","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111904184984900_B37","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111904184984900_B38","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.111.094425","article-title":"ACRIN 6665\/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression","volume":"53","author":"Van den Abbeele","year":"2012","journal-title":"J Nucl Med"},{"key":"2019111904184984900_B39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2019111904184984900_B40","author":"Brown","year":"2016"},{"issue":"4","key":"2019111904184984900_B41","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/2\/182\/1406190\/blood804641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/2\/182\/1406190\/blood804641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:20:12Z","timestamp":1574137212000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/2\/182\/37018\/Singleagent-ibrutinib-in-relapsed-or-refractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,11]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-09-804641","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,11]]}}}